Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Aggerholm, Anni  [Clear All Filters]
2022
Simonsen AT, Meggendorfer M, Hansen MH, Nederby L, Koch S, Hansen M, Rosenberg CA, Kern W, Nyvold CG, Aggerholm A, et al. Acute myeloid leukemia displaying clonal instability during treatment: implications for measurable residual disease assessments. Exp Hematol. 2022.
Petersen MA, Rosenberg CA, Brøndum RF, Aggerholm A, Kjeldsen E, Rahbek O, Ludvigsen M, Hasle H, Roug AS, Bill M. Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups. Br J Haematol. 2022.
2020
Soerensen JFrasez, Aggerholm A, Kerndrup GBirk, Hansen MCelik, Ewald IKathrine L, Bill M, Ebbesen LHyldahl, Rosenberg CAgerbo, Hokland P, Ludvigsen M, et al. Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation. Blood Adv. 2020;4(5):885-892.
Simonsen ATranberg, Bill M, Rosenberg CAgerbo, Hansen MHøy, Møller PLoof, Kjeldsen E, Johansen KDalsgaard, Ommen HBeier, Nederby L, Aggerholm A, et al. Unraveling clonal heterogeneity at the stem cell level in myelodysplastic syndrome: In pursuit of cell subsets driving disease progression. Leuk Res. 2020;92:106350.
2019
Kjaer L, Skov V, Andersen MTolstrup, Aggerholm A, Clair P, Gniot M, Soeby K, Udby L, Dorff MHelleberg, Hasselbalch H, et al. Variant specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay. Eur J Haematol. 2019.